Department of Medicine, Brigham and Women's Hospital, Boston, Mass.
Department of Medicine, Harvard Medical School, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, and the Jeff and Penny Vinik Center, Boston, Mass.
J Allergy Clin Immunol Pract. 2019 Apr;7(4):1174-1180. doi: 10.1016/j.jaip.2018.10.032. Epub 2018 Nov 2.
Aspirin challenge and desensitization remains the criterion standard in diagnosis and treatment for patients with aspirin-exacerbated respiratory disease (AERD), but the protocols can be time and resource intensive.
To provide evidence that oral aspirin challenge and desensitization can be safely performed in an outpatient setting in 1 day.
Forty-four patients with a confirmed diagnosis of AERD, stable asthma, and baseline FEV value greater than or equal to 70% of predicted completed an oral aspirin challenge and desensitization protocol. The starting dose was 40.5 mg with escalating doses of aspirin (81, 162.5, 325 mg) at 90-minute intervals until symptoms were provoked. Desensitization was defined as tolerating a repeated administration of the provocative aspirin dose and at least 1 subsequent dose, bringing the total aspirin ingested during the in-clinic desensitization to 325 mg or more.
Ninety-three percent of patients completed the challenge and desensitization in 1 day, with an average protocol completion time of 9 hours and 29 minutes. Two patients (4.6%) chose to complete the protocol over 2 days. One patient (2.3%) was discontinued from the protocol because of ongoing abdominal discomfort and diarrhea. No patient required epinephrine, emergency department visit, or hospitalization.
Patients with AERD on a stable asthma regimen and with a baseline FEV value greater than or equal to 70% can be safely desensitized to aspirin using a 90-minute dose escalation protocol, starting at a dose of 40.5 mg, and defining desensitization as tolerance of the repeated provocation dose and at least 1 subsequent aspirin dose, bringing total cumulative daily dose to 325 mg or more. This protocol can routinely be completed in 1 day.
阿司匹林激发试验和脱敏治疗仍然是诊断和治疗阿司匹林加重性呼吸系统疾病(AERD)患者的金标准,但这些方案可能既耗时又耗资源。
提供证据表明,口服阿司匹林激发试验和脱敏治疗可以在 1 天内在门诊安全进行。
44 例确诊为 AERD、稳定型哮喘且基线 FEV 值大于或等于预计值的 70%的患者完成了口服阿司匹林激发试验和脱敏方案。起始剂量为 40.5mg,每隔 90 分钟递增剂量的阿司匹林(81、162.5、325mg),直至出现症状。脱敏定义为耐受重复给予激发剂量的阿司匹林和至少 1 次后续剂量,使门诊脱敏期间摄入的总阿司匹林剂量达到 325mg 或更多。
93%的患者在 1 天内完成了挑战和脱敏,平均方案完成时间为 9 小时 29 分钟。2 名患者(4.6%)选择分 2 天完成方案。1 名患者(2.3%)因持续腹痛和腹泻而退出方案。没有患者需要使用肾上腺素、急诊就诊或住院治疗。
在稳定型哮喘治疗方案下且基线 FEV 值大于或等于预计值的 70%的 AERD 患者,可以安全地使用 90 分钟剂量递增方案进行阿司匹林脱敏治疗,起始剂量为 40.5mg,将脱敏定义为耐受重复给予激发剂量和至少 1 次后续的阿司匹林剂量,使总累积每日剂量达到 325mg 或更多。该方案通常可以在 1 天内完成。